文献速递泌尿生殖腹部MR

临床怀疑前列腺癌时行前列腺MRI的癌症检出率与异常判读率

Cancer Detection Rate and Abnormal Interpretation Rate of Prostate MRI Performed for Clinical Suspicion of Prostate Cancer.
PubMed 文献 · J Am Coll Radiol · 2023-10-10

该回顾性单机构三中心研究纳入2017至2021年因临床怀疑前列腺癌而行MRI的患者9686例次,排除已知前列腺癌者。按PI-RADS 3-5定义为异常MRI计算异常判读率,按异常MRI中检出Gleason评分≥7的临床显著前列腺癌计算癌症检出率,并分析病理确认率校正及活检状态分层结果。

要点

  • 三中心异常判读率为42.3%至47.2%,癌症检出率为20.0%至27.2%。
  • 经病理确认率校正后癌症检出率为22.8%至30.1%。
  • 初次活检患者癌症检出率24.2%至33.5%,既往阴性活检者11.7%至14.2%。

核心结论

  • 作者报告了因临床怀疑前列腺癌而行前列腺MRI的癌症检出率与异常判读率,并认为机构间比较时癌症检出率需按病理确认率和MRI前活检状态进行校正。

研究设计与样本

  • 回顾性单机构三中心研究,纳入2017年至2021年间因临床怀疑前列腺癌而行MRI的患者,排除已知前列腺癌者,共9686例次检查(8643名独立患者)。
  • 从放射学报告中提取患者水平的PI-RADS评分作为判读依据,参考标准为病理证实的Gleason评分≥7的临床显著前列腺癌。

诊断标准与关键数值

  • 异常判读率定义为PI-RADS评分3-5的异常MRI例数除以MRI总例数。
  • 癌症检出率定义为异常MRI中检出的临床显著前列腺癌(Gleason评分≥7)例数除以MRI总例数。
  • 中心I异常判读率45.4%、癌症检出率23.8%、病理确认率校正后癌症检出率27.6%。
  • 中心II异常判读率47.2%、癌症检出率20.0%、病理确认率校正后癌症检出率22.8%。
  • 中心III异常判读率42.3%、癌症检出率27.2%、病理确认率校正后癌症检出率30.1%。

临床应用与阅片要点

  • 三中心病理确认率范围为81.6%至88.0%。
  • 初次活检患者异常判读率45.5%至52.6%,癌症检出率24.2%至33.5%。
  • 既往阴性活检患者异常判读率27.2%至39.8%,癌症检出率11.7%至14.2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To report cancer detection rate (CDR) and abnormal interpretation rate (AIR) in prostate MRI performed for clinical suspicion of prostate cancer (PCa).

MATERIALS AND METHODS: This retrospective single-institution, three-center study included patients who underwent MRI for clinical suspicion of PCa between 2017 and 2021. Patients with known PCa were excluded. Patient-level Prostate Imaging-Reporting and Data System (PI-RADS) score was extracted from the radiology report. AIR was defined as number of abnormal MRI (PI-RADS score 3-5) / total number of MRIs. CDR was defined as number of clinically significant PCa (csPCa: Gleason score ≥7) detected at abnormal MRI / total number of MRI. AIR, CDR, and CDR adjusted for pathology confirmation rate were calculated for each of three centers and pre-MRI biopsy status (biopsy-naive and previous negative biopsy).

RESULTS: A total of 9,686 examinations (8,643 unique patients) were included. AIR, CDR, and CDR adjusted for pathology confirmation rate were 45.4%, 23.8%, and 27.6% for center I; 47.2%, 20.0%, and 22.8% for center II; and 42.3%, 27.2%, and 30.1% for center III, respectively. Pathology confirmation rate ranged from 81.6% to 88.0% across three centers. AIR and CDR for biopsy-naive patients were 45.5% to 52.6% and 24.2% to 33.5% across three centers, respectively, and those for previous negative biopsy were 27.2% to 39.8% and 11.7% to 14.2% across three centers, respectively.

CONCLUSION: We reported CDR and AIR in prostate MRI for clinical suspicion of PCa. CDR needs to be adjusted for pathology confirmation rate and pre-MRI biopsy status for interfacility comparison.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Nagayama H, Nakai H, Takahashi H, et al. Cancer Detection Rate and Abnormal Interpretation Rate of Prostate MRI Performed for Clinical Suspicion of Prostate Cancer. J Am Coll Radiol. 2023. PMID: 37820833. doi:10.1016/j.jacr.2023.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。